-$0.17 Earnings Per Share Expected for AzurRx BioPharma Inc (NASDAQ:AZRX) This Quarter
Analysts expect AzurRx BioPharma Inc (NASDAQ:AZRX) to post earnings of ($0.17) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for AzurRx BioPharma’s earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.20). AzurRx BioPharma posted earnings of ($0.24) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 29.2%. The business is expected to report its next quarterly earnings report on Monday, April 6th.
According to Zacks, analysts expect that AzurRx BioPharma will report full year earnings of ($0.77) per share for the current fiscal year, with EPS estimates ranging from ($0.82) to ($0.69). For the next financial year, analysts forecast that the company will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.72) to ($0.41). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow AzurRx BioPharma.
A number of brokerages have recently commented on AZRX. HC Wainwright set a $5.00 target price on AzurRx BioPharma and gave the stock a “buy” rating in a report on Friday, October 18th. Maxim Group set a $3.00 target price on AzurRx BioPharma and gave the stock a “buy” rating in a report on Tuesday, October 15th. Six equities research analysts have rated the stock with a buy rating, AzurRx BioPharma currently has an average rating of “Buy” and an average target price of $7.10.
Shares of AzurRx BioPharma stock traded up $0.01 on Wednesday, reaching $0.75. The company had a trading volume of 133,649 shares, compared to its average volume of 195,218. The firm has a market cap of $19.70 million, a price-to-earnings ratio of -0.86 and a beta of 2.12. The firm’s 50-day moving average price is $0.70 and its two-hundred day moving average price is $1.15. AzurRx BioPharma has a 1 year low of $0.42 and a 1 year high of $3.10.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.